Mutation dynamics from diagnosis to relapse in acute myeloid leukemia with chromosomal 7 deletions

Monosomy 7 and 7q deletions (-7/del(7q)) are the most common adverse cytogenetic event in acute myeloid leukemia (AML), linked to high relapse rates. We analyzed 115 AML patients with -7/del(7q) who achieved remission after induction therapy to characterize the mutational landscape from diagnosis to relapse. Median overall survival (OS) was 10.4 months, with improved survival in patients without TP53 mutation (13.04 vs. 8.6 months) or complex karyotype (12.4 vs. 8.6 months). TP53 mutations were most frequent (67% of cases at diagnosis) and persisted in 97% of patients at relapse. At time of relapse, patients with TP53 mutations had fewer co-occurring mutations in ASXL1, RUNX1, NRAS, PTPN11 and SRSF2 compared to TP53 wild-type patients. Patients with mutated TP53 and co-mutation in NF1, BCORL1, GATA2, or RUNX1 had shorter relapse-free survival (2 vs. 5 months) and OS (7.2 vs. 10.4 months) than those with TP53 mutation alone. Allogeneic transplant improved OS significantly, regardless of TP53 status.

Authors

Institutions

Publication Details

Journal
Leukemia & lymphoma/Leukemia and lymphoma
Published
2025-03-31
DOI
https://doi.org/10.1080/10428194.2025.2477723
Citations
2
Primary Topic
Acute Myeloid Leukemia Research
Type
article
Field-Weighted Citation Impact
3.54
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Mutation dynamics from diagnosis to relapse in acute myeloid leukemia with chromosomal 7 deletions

Courtney Denton Dinardo, Ehsan Irajizad, Beenu Thakral, Tapan Mahendra Kadia et al.
2 citations
Leukemia & lymphoma/Leukemia and lymphoma
Acute Myeloid Leukemia Research
3.54
article

Mutation dynamics from diagnosis to relapse in acute myeloid leukemia with chromosomal 7 deletions

Courtney Denton Dinardo, Ehsan Irajizad, Beenu Thakral, Tapan Mahendra Kadia, Koji Sasaki, Sherry A. Pierce, Álex Bataller, Patrick K. Reville, Musa E. Yilmaz, Bofei Wang, Alexandre Bazinet, Gautam Borthakur, Farhad Ravandi, Hussein A. Abbas, Enes Dasdemir, Danielle Hammond, Nicholas James Short, Naval Daver, Eitan Kugler
article en
2 citations

Abstract

Monosomy 7 and 7q deletions (-7/del(7q)) are the most common adverse cytogenetic event in acute myeloid leukemia (AML), linked to high relapse rates. We analyzed 115 AML patients with -7/del(7q) who achieved remission after induction therapy to characterize the mutational landscape from diagnosis to relapse. Median overall survival (OS) was 10.4 months, with improved survival in patients without TP53 mutation (13.04 vs. 8.6 months) or complex karyotype (12.4 vs. 8.6 months). TP53 mutations were most frequent (67% of cases at diagnosis) and persisted in 97% of patients at relapse. At time of relapse, patients with TP53 mutations had fewer co-occurring mutations in ASXL1, RUNX1, NRAS, PTPN11 and SRSF2 compared to TP53 wild-type patients. Patients with mutated TP53 and co-mutation in NF1, BCORL1, GATA2, or RUNX1 had shorter relapse-free survival (2 vs. 5 months) and OS (7.2 vs. 10.4 months) than those with TP53 mutation alone. Allogeneic transplant improved OS significantly, regardless of TP53 status.

Leukemia & lymphoma/Leukemia and lymphomaVol. 66(7)
The University of Texas MD Anderson Cancer Center (US), University of Houston (US)
Openalex Percentile: Top 9%
Acute Myeloid Leukemia Research
3.54
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.